Developmental programming: Exposure to testosterone excess disrupts steroidal and metabolic environment in pregnant sheep

Endocrinology

Volumn 156, Issue 6, 2015, Pages 2323-2337

  Abi Salloum, B ^a   Veiga Lopez, A ^a,e   Abbott, D H ^d   Burant, C F ^b   Padmanabhan, Vasantha ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; AMINO ACID; FATTY ACID; FLUTAMIDE; GLUCOSE; INSULIN; PROGESTERONE; ROSIGLITAZONE; STEROID; TESTOSTERONE; TESTOSTERONE PROPIONATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FATTY ACID OXIDATION; FEMALE; GESTATIONAL AGE; HOMEOSTASIS; MATERNAL BLOOD; MITOCHONDRIAL RESPIRATION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SHEEP; UMBILICAL CORD; ANIMAL; BIRTH WEIGHT; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; REPRODUCTION;

ANIMALS; BIRTH WEIGHT; BLOOD GLUCOSE; FEMALE; FLUTAMIDE; INSULIN; PREGNANCY; PROGESTERONE; REPRODUCTION; SHEEP; STEROIDS; TESTOSTERONE; THIAZOLIDINEDIONES;

EID: 84930441308     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-2006     Document Type: Article

References (85)

1. Barker DJ. The developmental origins of adult disease. J Am Coll Nutr. 2004;(suppl 6):588S-595S.
2. Fowden AL, Giussani DA, Forhead AJ. Intrauterine programming of physiological systems: causes and consequences. Physiology (Bethesda). 2006;21:29-37.
3. Aceti A, Santhakumaran S, Logan KM, et al. The diabetic pregnancy and offspring blood pressure in childhood: a systematic review and meta-analysis. Diabetologia. 2012;11:3114-3127.
4. Poston L. Developmental programming and diabetes-the human experience and insight from animal models. Best Pract Res Clin Endocrinol Metab. 2010;4:541-552.
5. Fowden AL, Forhead AJ. Endocrine regulation of feto-placental growth. Horm Res. 2009;72:257-265.
6. Bourguignon JP, Parent AS. Early homeostatic disturbances of human growth and maturation by endocrine disrupters. Curr Opin Pediatr. 2010;4:470-477.
7. Witchel SF, Recabarren SE, González F, et al. Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine. 2012;3:526-534.
8. Vejrazkova D, Vcelak J, Vankova M, et al. Steroids and insulin resistance in pregnancy. J Steroid Biochem Mol Biol. 2014;139:122-129.
9. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;3:245-291.
10. Maliqueo M, Lara HE, Sánchez F, Echiburú B, Crisosto N, Sir- Petermann T. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;166:151-155.
11. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997;130:128-133.
12. Sir-Petermann T, Hitchsfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod. 2005;20:2122-2126.
13. Laitinen J, Taponen S, Martikainen H, et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord. 2003;27:710-715.
14. Sadrzadeh S, Klip WAJ, Broekmans FJM, et al. Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort. Hum Reprod. 2003;18:2225-2230.
15. Legro RS, Roller RL, Dodson WC, Stetter CM, Kunselman AR, Dunaif A. Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. J Clin Endocrinol Metab. 2010;95:789-799.
16. Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet. 1997;350:1131-1135.
17. Davies MJ, March WA, Willson KJ, Giles LC, Moore VM. Birth-weight and thinness at birth independently predict symptoms of polycystic ovary syndrome in adulthood. Hum Reprod. 2012;27:1475-1480.
18. Mumm H, Kamper-Jørgensen M, Nybo Andersen AM, Glintborg D, Andersen M. Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973-1991. Fertil Steril. 2013;99:777-782.
19. Uzelac PS, Li X, Lin J, et al. Dysregulation of leptin and testosterone production and their receptor expression in the human placenta with gestational diabetes mellitus. Placenta. 2010;3:581-588.
20. Vambergue A, Fajardy I. Consequences of gestational and pregestational diabetes on placental function and birth weight. World J Diabetes. 2011;2:196-200.
21. Taricco E, Radaelli T, Nobile de Santis MS, Cetin I. Foetal and placental weights in relation to maternal characteristics in gestational diabetes. Placenta. 2003;4:343-347.
22. Veiga-Lopez A, Steckler TL, Abbott DH, et al. Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol Reprod. 2011;84:87-96.
23. Abbott DH, Bruns CR, Barnett DK, et al. Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am J Physiol Endocrinol Metab. 2010;299:E741-E751.
24. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab. 2000;85:1206-1210.
25. Nicol LE, O'Brien TD, Dumesic DA, Grogan T, Tarantal AF, Abbott DH. Abnormal infant islet morphology precedes insulin resistance in PCOS-like monkeys. PLoS One. 2014;9:e106527.
26. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod. 2002;17:2573-2579.
27. Mehrabian F, Kelishadi R. Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls. J Res Med Sci. 2012;17:207-211.
28. Manikkam M, Crespi EJ, Doop DD, et al. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology. 2004;145:790-798.
29. Alexandre-Gouabau MC, Courant F, Moyon T, et al. Maternal and cord blood LC-HRMS metabolomics reveal alterations in energy and polyamine metabolism, and oxidative stress in very-low birth weight infants. J Proteome Res. 2013;12:2764-2778.
30. Alvino G, Cozzi V, Radaelli T, Ortega H, Herrera E, Cetin I. Maternal and fetal fatty acid profile in normal and intrauterine growth restriction pregnancies with and without preeclampsia. Pediatr Res. 2008;64:615-620.
31. Lin G, Liu C, Feng C, et al. Metabolomic analysis reveals differences in umbilical vein plasma metabolites between normal and growth-restricted fetal pigs during late gestation. J Nutr. 2012;142:990-998.
32. Favretto D, Cosmi E, Ragazzi E, et al. Cord blood metabolomic profiling in intrauterine growth restriction. Anal Bioanal Chem. 2012;402:1109-1121.
33. Beckett EM, Astapova O, Steckler TL, Veiga-Lopez A1, Padmanabhan V. Developmental programing: impact of testosterone on placental differentiation. Reproduction. 2014;148:199-209.
34. Roberts CT, Kind KL, Earl RA, et al. Circulating insulin-like growth factor (IGF)-I and IGF binding proteins-1 and -3 and placental development in the guinea-pig. Placenta. 2002;23:763-770.
35. Vonnahme KA, Hess BW, Hansen TR, et al. Maternal undernutrition from early- to mid-gestation leads to growth retardation, cardiac ventricular hypertrophy, and increased liver weight in the fetal sheep. Biol Reprod. 2003;69:133-140.
36. Committee on the Nutrient Requirements of Small Ruminants NRC. Nutrient Requirements of Small Ruminants. Sheep, Goats, Cervids, and New World Camelids. Washington, DC: The National Academy Press; 2007.
37. Padmanabhan V, Evans NP, Dahl GE, McFadden KL, Mauger DT, Karsch FJ. Evidence for short or ultrashort loop negative feedback of gonadotropin-releasing hormone secretion. Neuroendocrinology. 1995;62:248-258.
38. Niswender GD, Reichert LE, Midgley AR, Nalbandov AV. Radio-immunoassay for bovine and ovine luteinizing hormone. Endocrinology. 1969;84:1166-1173.
39. Padmanabhan V, McFadden K, Mauger DT, Karsch FJ, Midgley AR Jr. Neuroendocrine control of follicle-stimulating hormone (FSH) secretion: I. Direct evidence for separate episodic and basal components of FSH secretion. Endocrinology. 1997;138:424-432.
40. Padmanabhan V, Veiga-Lopez A, Abbott DH, Recabarren SE, Herkimer C. Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology. 2010;151:595-605.
41. Padmanabhan V, Veiga-Lopez A. Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol. 2012;373:8-20.
42. Tserng K-Y, Kliegman RM, Miettinen E-L, Kalhan SC. A rapid, simple, and sensitive procedure for the determination of free fatty acids in plasma using glass capillary column gas-liquid chromatography. J Lipid Res. 1981;22:852-858.
43. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
44. Kugler F, Graneis S, Schreiter PP, Stintzing FC, Carle R. Determination of free amino compounds in betalainic fruits and vegetables by gas chromatography with flame ionization and mass spectrometric detection. J Agric Food Chem. 2006;54:4311-4318.
45. Pappa KI, Vlachos G, Theodora M, Roubelaki M, Angelidou K, Antsaklis A. Intermediate metabolism in association with the amino acid profile during the third trimester of normal pregnancy and diet-controlled gestational diabetes. Am J Obstet Gynecol. 2007;196:65.e1-e5.
46. Bazer FW, Spencer TE, Thatcher WW. Growth and development of the ovine conceptus. J Anim Sci. 2012;90:159-170.
47. Spencer TE, Bazer FW. Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front Biosci. 2002;7:d1879-d1898.
48. Parraguez VH, Urquieta B, De los Reyes M, González-Bulnes A, Astiz S, Muñoz A. Steroidogenesis in sheep pregnancy with intra-uterine growth retardation by high-altitude hypoxia: effects of maternal altitudinal status and antioxidant treatment. Reprod Fertil Dev. 2013;25:639-645.
49. Nisbet AD, Horne CH, Jandial V, Bremner RD, Cruickshank N, Sutcliffe RG. Measurement of plasma placental proteins and estriol in the detection of intrauterine growth retardation. Eur J Obstet Gynecol Reprod Biol. 1982;13:333-334.
50. Laurin J, Persson PH, Fernlund P. The efficacy of biochemical assays in assessing an IUGR risk-group, preselected with ultrasound fetometry. Eur J Obstet Gynecol Reprod Biol. 1987;24:177-187.
51. Hewitt DP, Mark PJ, Waddell BJ. Glucocorticoids prevent the normal increase in placental vascular endothelial growth factor expression and placental vascularity during late pregnancy in the rat. Endocrinology. 2006;147:5568-5574.
52. Steckler T, Wang J, Bartol FF, Roy SK, Padmanabhan V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology. 2005;146:3185-3193.
53. Sawyer HR. Structural and functional properties of the corpus luteum of pregnancy. J Reprod Fertil. 1995;(suppl 49):97-110.
54. Al-Gubory KH, Solari A, Mirman B. Effects of luteectomy on the maintenance of pregnancy, circulating progesterone concentrations and lambing performance in sheep. Reprod Fertil Dev. 1999;11:317-322.
55. Schombee CJA. Sensitivity of the corpus luteum towards prostaglandin F2α (PGF 2α) during the gestation period. Agricola. 1998-99;95-97.
56. France JT, Mason JI, Magness RR, Murry BA, Rosenfeld CR. Ovine placental aromatase: studies of activity levels, kinetic characteristics and effects of aromatase inhibitors. J Steroid Biochem. 1987;28:155-160.
57. Luense LJ, Veiga-Lopez A, Padmanabhan V, Christenson LK. Developmental programming: gestational testosterone treatment alters fetal ovarian gene expression. Endocrinology. 2011;152:4974-4983.
58. Al-Gubory KH, Blanc MR, Poirier JC, Solari A, Martinet J. Evidence that the corpus luteum of pregnancy contributes to the control of tonic secretion of LH in the ewe. J Reprod Fertil. 1989;85:125-131.
59. Al-Gubory KH, Blanc MR, Martinet J. Role of the corpus luteum of pregnancy in controlling pituitary gonadotrophin secretion during the early postpartum period in the ewe. J Reprod Fertil. 1989;86:697-703.
60. Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 1998;83:3558-3562.
61. Li HP, Chen X, Li MQ. Gestational diabetes induces chronic hypoxia stress and excessive inflammatory response in murine placenta. Int J Clin Exp Pathol. 2013;6:650-659.
62. Kayemba-Kays S, Peters C, Geary MP, Hill NR, Mathews DR, Hindmarsh PC. Maternal hyperinsulinism and glycaemic status in the first trimester of pregnancy are associated with the development of pregnancy-induced hypertension and gestational diabetes. Eur J Endocrinol. 2013;168:413-418.
63. de Wilde MA, Veltman-Verhulst SM, Goverde AJ, et al. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome. Hum Reprod. 2014;29:1327-1336.
64. Wang Y, Zhao X, Zhao H, et al. Risks for gestational diabetes mellitus and pregnancy-induced hypertension are increased in polycystic ovary syndrome. Biomed Res Int. 2013;2013:182582.
65. Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:E447-E452.
66. Fowden AL, Moore T. Maternal-fetal resource allocation: co-operation and conflict. Placenta. 2012;33(suppl 2):e11-e15.
67. Lager S, Powell TL. Regulation of nutrient transport across the placenta. J Pregn. 2012;2012:179827.
68. Oey NA, Ruiter JP, Attié-Bitach T, Ijlst L, Wanders RJ, Wijburg FA. Fatty acid oxidation in the human fetus: implications for fetal and adult disease. J Inherit Metab Dis. 2006;29:71-75.
69. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008;10:151-156.
70. Mihalik SJ, Goodpaster BH, Kelley DE, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010;18:1695-1700.
71. Muoio DM, Neufer PD. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab. 2012;15:595-605.
72. Herrera E, Muñoz C, López-Luna P, Ramos P. Carbohydrate-lipid interactions during gestation and their control by insulin. Braz J Med Biol Res. 1994;27:2499-2519.
73. Xu Y, Wang Q, Cook TJ, Knipp GT. Effect of placental fatty acid metabolism and regulation by peroxisome proliferator activated receptor on pregnancy and fetal outcomes. J Pharm Sci. 2007;96:2582-2606.
74. Smith SA. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem Soc Trans. 2002;30:1086-1090.
75. Meyburg J, Schulze A, Kohlmueller D, Linderkamp O, Mayatepek E. Postnatal changes in neonatal acylcarnitine profile. Pediatr Res. 2001;49:125-129.
76. Akisu M, Bekler C, Yalaz M, Hüseyinov A, Kültürsay N. Free carnitine concentrations in cord blood in preterm and full-term infants with intrauterine growth retardation. Pediatr Int. 2001;43:107-108.
77. Horgan RP, Broadhurst DI, Walsh SK, et al. Metabolic profiling uncovers a phenotypic signature of small for gestational age in early pregnancy. J Proteome Res. 2011;10:3660-3673.
78. Luan H, Meng N, Liu P, et al. Pregnancy-induced metabolic phenotype variations in maternal plasma. J Proteome Res. 2014;13:1527-1536.
79. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(suppl 2):S112-S119.
80. Zang H, Ryden M, Wahlen K, et al. 2007 Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. Fertil Steril. 2007;88:100-106.
81. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci. 2003;58:M1103-M1110.
82. Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78:920-926.
83. Fowden AL, Ward JW, Wooding FPB, Forhead AJ, Constancia M. Programming placental nutrient transport capacity. J Physiol. 2006;572(Pt 1):5-15.
84. Mark PJ, Smith J, Waddell BJ. Placental and fetal growth retardation following partial progesterone withdrawal in rat pregnancy. Placenta. 2006;27:208-214.
85. Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57:78R-86R.